ArticleMaterials today. Bio2026
Injectable chitosan-based hydrogel via in situ gelation modulates the inflammatory microenvironment and facilitates minimally invasive repair of peripheral nerve injury.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Controlled drug release and electroconductive performance of 3D printed scaffolds for neural tissue regeneration.Journal of materials science. Materials in medicine · 2026Article
- Plasticity, injury-induced reprogramming, and translational applications of Schwann cells in neural regeneration.Frontiers in cellular neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-transecting peripheral nerve injuries require effective inflammation control, support of axon regeneration, and strategies that minimize additional surgical trauma. Injectable hydrogels are attractive carriers for local therapy, and chitosan is a widely used biocompatible matrix; however, conventional chitosan systems often depend on acidic dissolution and crosslinking or cytotoxic crosslinkers, which may aggravate nerve injury and hinder clinical translation. Here, we develop an injectable chitosan-based hydrogel (IBU-CS-GP) in which ibuprofen is complexed with chitosan for solubility range expansion toward near-neutral pH, thereby permitting genipin-mediated crosslinking under near-physiological pH and resolving the mismatch between chitosan solubility and the optimal pH for genipin. The resulting hydrogel forms a stable depot after perineural injection, enabling minimally invasive in situ gelation and localized drug delivery. We characterize its physicochemical properties, ibuprofen release profile, and biosafety, and evaluate its immunomodulatory and pro-regenerative effects in vitro and in a rat sciatic nerve crush model. In vitro, the IBU-CS-GP hydrogel suppresses macrophage inflammatory activation and reduces pro-inflammatory mediator production, thereby promoting a repair-supportive phenotype; in parallel, it indirectly enhances endothelial and stromal cell activities involved in angiogenesis and matrix remodeling. In vivo, perineural injection results in sustained ibuprofen release, accompanied by accelerated recovery of gait and nerve conduction, better preservation of gastrocnemius muscle mass and architecture, and more organized axon regeneration. These data suggest that the IBU-CS-GP hydrogel is a promising minimally invasive local therapy for non-transecting peripheral nerve injuries, as it enables near-neutral-pH in situ gelation and modulates the post-injury microenvironment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.